Our top pick for
Building a portfolio
Utah Medical Products, Inc is a medical instruments & supplies business based in the US. Utah Medical Products shares (UTMD) are listed on the NASDAQ and all prices are listed in US Dollars. Utah Medical Products employs 181 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$76.47 - $107.63|
|50-day moving average||$88.03|
|200-day moving average||$86.81|
|Wall St. target price||N/A|
|Dividend yield||$1.12 (1.29%)|
|Earnings per share (TTM)||$2.94|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Utah Medical Products stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Utah Medical Products's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Utah Medical Products's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 30x. In other words, Utah Medical Products shares trade at around 30x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Utah Medical Products's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $20.9 million.
The EBITDA is a measure of a Utah Medical Products's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$42.2 million|
|Operating margin TTM||32.5%|
|Gross profit TTM||$25.5 million|
|Return on assets TTM||7.74%|
|Return on equity TTM||10.59%|
|Market capitalisation||$321.6 million|
TTM: trailing 12 months
There are currently 71,311 Utah Medical Products shares held short by investors – that's known as Utah Medical Products's "short interest". This figure is 2.4% down from 73,055 last month.
There are a few different ways that this level of interest in shorting Utah Medical Products shares can be evaluated.
Utah Medical Products's "short interest ratio" (SIR) is the quantity of Utah Medical Products shares currently shorted divided by the average quantity of Utah Medical Products shares traded daily (recently around 12107.130730051). Utah Medical Products's SIR currently stands at 5.89. In other words for every 100,000 Utah Medical Products shares traded daily on the market, roughly 5890 shares are currently held short.
However Utah Medical Products's short interest can also be evaluated against the total number of Utah Medical Products shares, or, against the total number of tradable Utah Medical Products shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Utah Medical Products's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Utah Medical Products shares in existence, roughly 20 shares are currently held short) or 0.0242% of the tradable shares (for every 100,000 tradable Utah Medical Products shares, roughly 24 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Utah Medical Products.
Find out more about how you can short Utah Medical Products stock.
Dividend payout ratio: 37.29% of net profits
Recently Utah Medical Products has paid out, on average, around 37.29% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.31% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Utah Medical Products shareholders could enjoy a 1.31% return on their shares, in the form of dividend payments. In Utah Medical Products's case, that would currently equate to about $1.12 per share.
While Utah Medical Products's payout ratio might seem fairly standard, it's worth remembering that Utah Medical Products may be investing much of the rest of its net profits in future growth.
Utah Medical Products's most recent dividend payout was on 1 April 2021. The latest dividend was paid out to all shareholders who bought their shares by 15 March 2021 (the "ex-dividend date").
Utah Medical Products's shares were split on a 3:2 basis on 21 March 1993. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Utah Medical Products shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Utah Medical Products shares which in turn could have impacted Utah Medical Products's share price.
Over the last 12 months, Utah Medical Products's shares have ranged in value from as little as $76.4696 up to $107.6257. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Utah Medical Products's is 0.2537. This would suggest that Utah Medical Products's shares are less volatile than average (for this exchange).
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization; LIBERTY urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN tool to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts.
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.